Nothing Special   »   [go: up one dir, main page]

CY1119383T1 - Αναστολεας ανθρωπινης ιστονικης μεθυλοτρανσφερασης εζη2 σε μορφη αλατος - Google Patents

Αναστολεας ανθρωπινης ιστονικης μεθυλοτρανσφερασης εζη2 σε μορφη αλατος

Info

Publication number
CY1119383T1
CY1119383T1 CY20171100290T CY171100290T CY1119383T1 CY 1119383 T1 CY1119383 T1 CY 1119383T1 CY 20171100290 T CY20171100290 T CY 20171100290T CY 171100290 T CY171100290 T CY 171100290T CY 1119383 T1 CY1119383 T1 CY 1119383T1
Authority
CY
Cyprus
Prior art keywords
methylother
anasteleas
histonic
salt
human
Prior art date
Application number
CY20171100290T
Other languages
English (en)
Inventor
Kevin Wayne Kuntz
Kuan-Chun Huang
Hyeong Wook Choi
Kristen Sanders
Steven Mathieu
Arani Chanda
Frank Fang
Original Assignee
Epizyme, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme, Inc. filed Critical Epizyme, Inc.
Publication of CY1119383T1 publication Critical patent/CY1119383T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Περιγράφεται ενταύθα το υδροβρωμικό Ν-((4,6-διμεθυλο-2-οξο-1,2-διυδροπυριδιν-3-υλ)μεθυλ)-5-(αιθυλο(τετραϋδρο-2Η-πυραν-4-υλ)αμινο)-4-μεθυλ-4'-(μορφολινομεθυλ)-[1,1’-διφαινυλ]-3-καρβοξαμίδιο. Επίσης περιγράφεται ενταύθα μια ειδική πολύμορφη μορφή της ένωσης.
CY20171100290T 2012-04-13 2017-03-06 Αναστολεας ανθρωπινης ιστονικης μεθυλοτρανσφερασης εζη2 σε μορφη αλατος CY1119383T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261624215P 2012-04-13 2012-04-13
PCT/US2013/036193 WO2013155317A1 (en) 2012-04-13 2013-04-11 Salt form of a human hi stone methyltransf erase ezh2 inhibitor

Publications (1)

Publication Number Publication Date
CY1119383T1 true CY1119383T1 (el) 2018-02-14

Family

ID=49328166

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171100290T CY1119383T1 (el) 2012-04-13 2017-03-06 Αναστολεας ανθρωπινης ιστονικης μεθυλοτρανσφερασης εζη2 σε μορφη αλατος
CY20191100981T CY1122883T1 (el) 2012-04-13 2019-09-18 Ν-((4,6-διμεθυλ-2-οξο-l,2-διυδροπυριδιν-3-υλ)μεθυλ)-5-(αιθυλ (τετραϋδρο-2η-πυραν-4-υλ)αμινο)-4-μεθυλ-4'-(μορφολινομεθυλ)-[l,1'-διφαινυλ]-3-καρβοξαμιδιο υδροβρωμικο για χρηση στη θεραπεια μιας κυτταροπολλαπλασιαστικης διαταραχης του αιματολογικου συστηματος

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20191100981T CY1122883T1 (el) 2012-04-13 2019-09-18 Ν-((4,6-διμεθυλ-2-οξο-l,2-διυδροπυριδιν-3-υλ)μεθυλ)-5-(αιθυλ (τετραϋδρο-2η-πυραν-4-υλ)αμινο)-4-μεθυλ-4'-(μορφολινομεθυλ)-[l,1'-διφαινυλ]-3-καρβοξαμιδιο υδροβρωμικο για χρηση στη θεραπεια μιας κυτταροπολλαπλασιαστικης διαταραχης του αιματολογικου συστηματος

Country Status (25)

Country Link
US (6) US9394283B2 (el)
EP (4) EP4190777A1 (el)
JP (3) JP6255382B2 (el)
KR (3) KR20220123339A (el)
CN (2) CN108358899B (el)
AU (2) AU2013245878B2 (el)
BR (1) BR112014025508B1 (el)
CA (1) CA2870005C (el)
CY (2) CY1119383T1 (el)
DK (3) DK2836491T3 (el)
ES (3) ES2617379T3 (el)
HR (2) HRP20170295T1 (el)
HU (3) HUE031976T2 (el)
IL (4) IL282732B2 (el)
IN (1) IN2014DN09068A (el)
LT (2) LT3184523T (el)
MX (1) MX362339B (el)
NZ (1) NZ700761A (el)
PL (3) PL3184523T3 (el)
PT (3) PT3184523T (el)
RS (2) RS59392B1 (el)
RU (1) RU2658911C2 (el)
SG (3) SG11201406468YA (el)
SI (2) SI3184523T1 (el)
WO (1) WO2013155317A1 (el)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
KR20230004871A (ko) 2012-04-13 2023-01-06 에피자임, 인코포레이티드 암 치료용 병용 요법
SG11201406468YA (en) * 2012-04-13 2015-01-29 Epizyme Inc Salt form of a human hi stone methyltransf erase ezh2 inhibitor
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
JP6351182B2 (ja) 2012-10-15 2018-07-04 エピザイム，インコーポレイティド ガンの治療方法
AU2013331380B2 (en) * 2012-10-15 2018-03-22 Epizyme, Inc. Substituted benzene compounds
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CA2910873A1 (en) 2013-04-30 2014-11-06 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
CA2917463A1 (en) 2013-07-10 2015-01-15 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
PE20161273A1 (es) 2013-10-16 2016-12-18 Epizyme Inc Forma salina de hidrocloruro para la inhibicion de ezh2
JP2016533364A (ja) * 2013-10-18 2016-10-27 エピザイム，インコーポレイティド 癌を処置する方法
US9738630B2 (en) 2013-11-19 2017-08-22 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
KR20210117347A (ko) 2013-12-06 2021-09-28 에피자임, 인코포레이티드 암 치료를 위한 병용 요법
IL309539A (en) 2014-06-17 2024-02-01 Epizyme Inc EZH2 inhibitors for the treatment of lymphoma
WO2015195862A1 (en) 2014-06-20 2015-12-23 Constellation Pharmaceuticals, Inc. Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4s5-e]azepin-4-yl)acetamide
CN112168967A (zh) 2014-10-16 2021-01-05 Epizyme股份有限公司 治疗癌症的方法
EP3220916B1 (en) * 2014-11-17 2023-04-19 Epizyme, Inc. Method for treating cancer with n-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl) amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ｅｚｈ２抑制劑
AU2016252546A1 (en) 2015-04-20 2017-11-02 Epizyme, Inc. Combination therapy for treating cancer
MX2017015938A (es) 2015-06-10 2018-11-09 Epizyme Inc Inhibidores de ezh2 para el tratar linfomas.
CN108025191A (zh) 2015-08-24 2018-05-11 Epizyme股份有限公司 治疗癌症的方法
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
JP2019503391A (ja) 2016-01-29 2019-02-07 エピザイム，インコーポレイティド 癌を処置するための併用療法
CA3025933A1 (en) 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
EP3471830A4 (en) 2016-06-17 2020-02-26 Epizyme Inc EZH2 INHIBITORS TO TREAT CANCER
EP3529242A1 (en) 2016-10-19 2019-08-28 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
US11214561B2 (en) * 2017-01-25 2022-01-04 Ancureall Pharmaceutical (Shanghai) Co., Ltd. Histone methyltransferase EZH2 inhibitor, preparation method and pharmaceutical use thereof
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
CN110944628A (zh) 2017-06-02 2020-03-31 Epizyme股份有限公司 使用ezh2抑制剂治疗癌症
CA3074720A1 (en) 2017-09-05 2019-03-14 Epizyme, Inc. Combination therapy for treating cancer
CA3104209A1 (en) 2018-07-09 2020-01-16 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
WO2021035194A1 (en) 2019-08-22 2021-02-25 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
CN115175904A (zh) * 2019-12-20 2022-10-11 Epizyme股份有限公司 Ezh2抑制剂的结晶氢溴酸盐、其制备和用于治疗癌症的药物组合物
WO2022208552A1 (en) * 2021-03-31 2022-10-06 Msn Laboratories Private Limited, R&D Center Crystalline forms of [1,1'-Biphenyl]-3-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:1) and process for its preparation thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0733729A (ja) 1993-07-26 1995-02-03 Kirin Brewery Co Ltd Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法
EP0686625B1 (en) 1993-12-27 1999-05-26 Eisai Co., Ltd. Anthranilic acid derivative
DE19516776A1 (de) 1995-05-10 1996-11-14 Boehringer Ingelheim Int Chromatin-Regulatorgene
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
JP3906935B2 (ja) 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
JP2002525352A (ja) 1998-09-30 2002-08-13 ザ、プロクター、エンド、ギャンブル、カンパニー ２−置換ケトアミド
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
WO2002053543A1 (fr) 2000-12-28 2002-07-11 Shionogi & Co., Ltd. Derive de pyridone ayant une affinite pour le recepteur cannabinoide de type 2
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
EP1477186B1 (en) 2002-02-19 2009-11-11 Shionogi & Co., Ltd. Antipruritics
TW200306155A (en) 2002-03-19 2003-11-16 Du Pont Benzamides and advantageous compositions thereof for use as fungicides
US7442685B2 (en) 2003-06-13 2008-10-28 The University Of North Carolina At Chapel Hill DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
RU2006138036A (ru) * 2004-03-30 2008-05-10 Чирон Корпорейшн (Us) Производные замещенного тиофена в качестве противораковых средств
EP1765994B1 (en) 2004-06-01 2009-11-18 The University of North Carolina at Chapel Hill Reconstituted histone methyltransferase complex and methods of identifying modulators thereof
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
ATE494548T1 (de) 2005-06-02 2011-01-15 Univ North Carolina Reinigung, charakterisierung und wiederherstellung einer ubiquitin-e3-ligase
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
PE20110285A1 (es) 2005-10-19 2011-06-04 Gruenenthal Chemie Derivados de sulfonamidofenil propionamida como ligandos del receptor vaniloide del subtipo 1
EP1951672B1 (en) 2005-10-21 2011-05-25 Merck Sharp & Dohme Corp. Potassium channel inhibitors
US20090203057A1 (en) 2005-10-28 2009-08-13 Yi Zhang Protein demethylases comprising a jmjc domain
KR20080080173A (ko) 2005-12-14 2008-09-02 브리스톨-마이어스 스큅 컴퍼니 세린 프로테아제 억제제로서 유용한 6-원 헤테로사이클
CA2623271A1 (en) 2006-01-20 2007-08-02 The University Of North Carolina At Chapel Hill Interaction between dot1l polypeptide and calm-af10 fusion protein as a therapeutic target for leukemia
KR20080110905A (ko) 2006-05-15 2008-12-19 아이알엠 엘엘씨 테레프탈라메이트 화합물 및 조성물, 및 ｈｉｖ 인테그라제억제제로서의 그들의 용도
WO2007136592A2 (en) 2006-05-18 2007-11-29 Amphora Discovery Corporation 2-0x0-l,2-dihydr0quin0line derivatives, compositions, and uses thereof as antiproliferative agents
WO2008108825A2 (en) 2006-10-10 2008-09-12 Burnham Institute For Medical Research Neuroprotective compositions and methods
AU2008219166B2 (en) 2007-02-16 2013-05-16 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
WO2008113006A1 (en) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
DE102007017884A1 (de) 2007-04-13 2008-10-16 Grünethal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
US20090012031A1 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan EZH2 Cancer Markers
DE102007047737A1 (de) * 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
JP2011502148A (ja) 2007-10-31 2011-01-20 メルク・シャープ・エンド・ドーム・コーポレイション 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト
EA019974B1 (ru) 2007-12-19 2014-07-30 Кансер Рисерч Текнолоджи Лимитед 8-ЗАМЕЩЕННЫЕ ПИРИДО[2,3-b]ПИРАЗИНЫ И ИХ ПРИМЕНЕНИЕ
WO2009124137A2 (en) 2008-04-01 2009-10-08 Mount Sinai School Of Medicine Of New York University Method of suppressing gene transcription through histone lysine methylation
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
EP2335779A1 (en) 2008-08-08 2011-06-22 New York Blood Center Small Molecule Inhibitors of Retroviral Assembly & Maturation
FR2934995B1 (fr) 2008-08-14 2010-08-27 Sanofi Aventis Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique
US20120065247A1 (en) 2009-03-27 2012-03-15 Discoverybiomed, Inc. Modulating ires-mediated translation
US20110021362A1 (en) 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
US8329149B2 (en) 2009-12-30 2012-12-11 Avon Products, Inc. Topical lightening composition and uses thereof
ES2534804T3 (es) * 2010-05-07 2015-04-28 Glaxosmithkline Llc Indazoles
EA023788B1 (ru) * 2010-05-07 2016-07-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Производные индола и фармацевтические композиции на их основе
US8637509B2 (en) 2010-05-07 2014-01-28 Glaxosmithkline Llc Azaindazoles
RU2765155C2 (ru) 2010-09-10 2022-01-26 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
EP2646020B1 (en) 2010-12-01 2016-09-21 Glaxosmithkline LLC Indoles
EP2646454B1 (en) 2010-12-03 2015-07-08 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
AU2013232229B2 (en) 2012-03-12 2017-11-23 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
SG11201406468YA (en) * 2012-04-13 2015-01-29 Epizyme Inc Salt form of a human hi stone methyltransf erase ezh2 inhibitor
KR20230004871A (ko) 2012-04-13 2023-01-06 에피자임, 인코포레이티드 암 치료용 병용 요법
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
JP6351182B2 (ja) 2012-10-15 2018-07-04 エピザイム，インコーポレイティド ガンの治療方法
PE20161273A1 (es) 2013-10-16 2016-12-18 Epizyme Inc Forma salina de hidrocloruro para la inhibicion de ezh2

Also Published As

Publication number Publication date
JP6634058B2 (ja) 2020-01-22
CN108358899A (zh) 2018-08-03
US20190269692A1 (en) 2019-09-05
AU2018200168B2 (en) 2019-08-29
SG10201912109QA (en) 2020-02-27
JP2015512942A (ja) 2015-04-30
US20170143729A1 (en) 2017-05-25
US10245269B2 (en) 2019-04-02
JP6255382B2 (ja) 2017-12-27
KR20200066380A (ko) 2020-06-09
ES2617379T3 (es) 2017-06-16
PT3628670T (pt) 2022-12-02
CN108358899B (zh) 2021-07-27
ES2745016T3 (es) 2020-02-27
JP2018199740A (ja) 2018-12-20
IL296199B1 (en) 2024-08-01
SG10201608577RA (en) 2016-12-29
RS59392B1 (sr) 2019-11-29
US9394283B2 (en) 2016-07-19
RS55690B1 (sr) 2017-07-31
EP2836491A1 (en) 2015-02-18
US11491163B2 (en) 2022-11-08
CY1122883T1 (el) 2022-03-24
PL2836491T3 (pl) 2017-08-31
SI2836491T1 (sl) 2017-06-30
US20150065503A1 (en) 2015-03-05
IL235045A0 (en) 2014-12-31
RU2014145544A (ru) 2016-06-10
IL266165B (en) 2021-06-30
SI3184523T1 (sl) 2020-04-30
PT3184523T (pt) 2019-09-26
IL296199A (en) 2022-11-01
IL266165A (en) 2019-06-30
HUE060881T2 (hu) 2023-04-28
KR20150002730A (ko) 2015-01-07
IL235045B (en) 2019-05-30
EP3184523B1 (en) 2019-06-19
KR102120883B1 (ko) 2020-06-09
DK3628670T3 (da) 2022-12-05
US20180243316A1 (en) 2018-08-30
HUE031976T2 (en) 2017-08-28
PL3184523T3 (pl) 2019-12-31
JP2018002742A (ja) 2018-01-11
IN2014DN09068A (el) 2015-05-22
US10821113B2 (en) 2020-11-03
IL282732B (en) 2022-12-01
RU2658911C2 (ru) 2018-06-26
EP4190777A1 (en) 2023-06-07
KR20220123339A (ko) 2022-09-06
WO2013155317A1 (en) 2013-10-17
AU2018200168A1 (en) 2018-02-01
EP3184523A1 (en) 2017-06-28
CN104603130B (zh) 2018-04-27
LT3184523T (lt) 2020-02-10
US9872862B2 (en) 2018-01-23
EP3628670A1 (en) 2020-04-01
IL282732A (en) 2021-06-30
IL282732B2 (en) 2023-04-01
PL3628670T3 (pl) 2023-02-20
CA2870005C (en) 2021-06-22
MX2014012380A (es) 2015-07-23
SG11201406468YA (en) 2015-01-29
AU2013245878A1 (en) 2014-10-30
NZ700761A (en) 2016-09-30
KR102438340B1 (ko) 2022-08-30
ES2931316T3 (es) 2022-12-28
BR112014025508B1 (pt) 2020-11-17
CA2870005A1 (en) 2013-10-17
HRP20191653T1 (hr) 2020-02-21
EP2836491B1 (en) 2016-12-07
HUE045353T2 (hu) 2019-12-30
CN104603130A (zh) 2015-05-06
EP3628670B1 (en) 2022-10-12
US20210137936A1 (en) 2021-05-13
LT2836491T (lt) 2017-03-27
AU2013245878B2 (en) 2017-10-12
HRP20170295T1 (hr) 2017-04-21
US20230140327A1 (en) 2023-05-04
DK3184523T3 (da) 2019-08-19
MX362339B (es) 2019-01-11
DK2836491T3 (en) 2017-03-06
PT2836491T (pt) 2017-02-08
EP2836491A4 (en) 2015-09-16

Similar Documents

Publication Publication Date Title
CY1119383T1 (el) Αναστολεας ανθρωπινης ιστονικης μεθυλοτρανσφερασης εζη2 σε μορφη αλατος
MX2016004703A (es) Forma salina de hidrocloruro para la inhibicion de ezh2.
DK3220916T3 (da) Fremgangsmåde til behandling af cancer med n-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamid
CY1120703T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
CY1121625T1 (el) Αναστολεις prmt5 και χρησεις αυτων
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
ECSP23034537A (es) Formulaciones farmaceuticas
EA201300200A1 (ru) N-((6-аминопиридин-3-ил)метил)гетероарилкарбоксамиды в качестве ингибиторов калликреина в плазме
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
CY1118662T1 (el) Νεες δικυκλικες πυριδινονες
EA201692356A1 (ru) Гидрохлоридные соли n-(цианометил)-4-(2-(4-морфолинофениламино)пиримидин-4-ил)бензамида
EA201590911A1 (ru) АЛКИЛАМИДЗАМЕЩЁННЫЕ ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ МОДУЛЯЦИИ IL-12, IL-23 И/ИЛИ IFNα
EA201400854A1 (ru) 4-(бензоимидазол-2-ил)тиазольные соединения и родственные аза производные
TR201900680T4 (tr) CXCR3 Reseptör modülatörleri olarak hidroksialkil- piperazin türevleri.
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
NI201100051A (es) Sales de n - [ 6 - ( cis - 2, 6 - dimetil - morfolin - 4 - il ) - piridin - 3 - il ] - 2 - metil - 4' - ( trifluoro - metoxi ) - [ 1, 1' - bifenil] - 3 - carboxamida.
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2
EA201391744A1 (ru) Производные 2-амино-3-(имидазол-2-ил)-пиридин-4-она и их применение в качестве ингибиторов киназы рецептора vegf
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
EA201300092A1 (ru) Замещенные производные оксадиазола
EA201600166A1 (ru) Производные пиперидина и азепина как модуляторы рецептора прокинетицина
BR112015003996A2 (pt) derivados de oxazolidinona 3,4-substituída e seu uso como inibidores do canal de potássio ativado por cálcio
EA201491307A1 (ru) Терапевтическое применение имидазопиридиновых производных соединений
EA201891447A1 (ru) Кристаллическая форма 1,3-тиазол-5-илметил-[(2r,5r)-5-{[(2s)-2-[(метил-{[2-(пропан-2-ил)-1,3-тиазол-4-ил]метил}карбамоил)-мино]-4-(морфолин-4-ил)бутаноил-9-амино}-1,6-дифенилгексан-2-ил]карбамата или кобицистата